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The global financial crisis has hit biotech companies hard both in the US and Europe as venture 
capital dries up. Finding new sources of long-term financing for translating research into new 
therapeutics will be essential for maintaining innovation and new drug development by biotech 
companies.“In the midst of a perfect storm,” that’s 
where biotech firms are right now, says 
James Greenwood, head of the US 
Biotechnology Industry Organization. 
The global financial crisis has reduced 
venture capital, the essential funds that 
fuel biotech companies, to $16 billion in 
2008, a 46% decrease compared with 
2007, according to Ernst & Young audi-
tors. This means that half of the 370 pub-
licly traded US biotech companies lack 
funds to weather the current financial 
storm over the next 6 to 12 months. And 
stock markets will not be able to come to 
the rescue. Although biotech companies 
raised $1.9 billion on stock exchanges 
worldwide in 2007, only $5.8 million was 
raised in a single initial public offering in 
2008. Eleven American biotech compa-
nies filed for bankruptcy in 2008, and it 
is not clear how many others could share 
a similar fate.
“This will impact new innovative drug 
therapies,” says Angus Dalgleish, an 
oncology researcher at St. George’s 
Hospital Medical School in London and 
cofounder of the UK-based company 
Onyvax, which is developing cancer vac-
cines. “Only one good project is going to 
get funded for every ten that would be 
equally justifiable.” But the current crisis 
is not a complete surprise. “Whether or 
not we had this acute credit crisis, the 
biotech industry was already looking 
at a decline in financing,” says Richard 
Aldrich, a biotech investor in Boston, 
MA. In the US, the glory days of the 
biotech business started in 1982 with a 
very permissive financial climate “where 
people were willing to make crazy spec-
ulative bets,” but this came to an end 
around 2001, he says. And, in parallel, 
“the cost of getting a drug approved 
became so great, that we are not going 
to reap the benefits of all this great sci-
ence that’s been produced.” To trans-
form a scientific idea into a single drug can cost up to $800 million and may take 
10 to 12 years from the first lab experi-
ments to approval by the US Food and 
Drug Administration or the European 
Medicines Agency, according to Aldrich. 
“And the probability is high, that it’s not 
going to work at all. Biotech is just a bad 
investment proposition.”
Aldrich, however, is quick to note that 
there are still good opportunities. For 
example, one of Aldrich’s enterprises is 
Sirtris, a company in Cambridge, MA, 
developing small molecule drugs such 
as resveratrol that modulate sirtuin 
enzymes to treat aging-related diseases. 
Sirtris was bought last year by the phar-
maceutical giant GlaxoSmithKline for 
$720 million. “Broad biological platforms 
based on great science will always create 
value,” emphasizes Mark Levin, the for-
mer CEO of the biotech company Millen-
nium, who now heads up the technology 
investment group ThirdRockVentures. In 
the midst of the crisis, he invested $37 
million to start Constellation Pharma-
ceuticals, which is developing drugs that 
target chromatin-modifying enzymes, 
such as histone methyltransferases or 
demethylases, to reverse pathogenic 
epigenetic modifications. But despite 
these examples, the biotech business is 
“much more narrow now and more dif-
ficult,” says Aldrich.
The Shrinking World of Venture 
Capital
Phillip Sharp, who studies RNA at MIT 
in Cambridge, MA, has witnessed all 
of the ups and downs of the biotech 
industry. Thirty years ago, the 1993 
Nobel Prize winner cofounded Biogen-
Idec, which makes drugs to treat mul-
tiple sclerosis, rheumatoid arthritis, and 
Crohn’s disease with annual revenues 
of $4.1 billion in 2008. And in 2001, 
despite the bursting of the technology 
bubble, Sharp founded Alnylam, which Cell 13is developing therapeutics based on 
RNA interference technology. Although 
“venture capital ran to the hills,” Sharp 
not only helped to raise about $17 mil-
lion for initial financing for Alnylam but 
also took advantage of the pressure on 
other companies, who were letting tal-
ented personnel go. “Sometimes, it’s 
to your advantage to be able to have 
a great idea in a slow economic time, 
because then there is real talent avail-
able for you.” This is true now, too, 
but the downturn is so substantial this 
time, that Sharp is not so sure when or 
whether an “up” will come. “This crisis is 
different from anything I’ve experienced 
in the last 30 years,” he says.
Biotech companies are having to 
adjust. “The current situation favors low 
risk projects over high risk ones, and the 
high risk ones will be delayed and will 
require government or charity core sup-
port to progress,” says Dalgleish. With 
44% of US biotech companies having less 
than a year’s supply of cash according 
to Ernst & Young, companies are focus-
ing on the most advanced projects and 
laying off staff involved with more risky 
or less developed programs. And that’s 
true globally too. This year, Santhera, 
a Swiss company developing drugs to 
treat neuromuscular diseases, closed its 
in-house drug discovery program, let-
ting go of 26 of the 82-person workforce. 
In the US alone, 2.4% of the estimated 
128,200 biotech employees in 2007 lost 
their jobs in 2008, and according to a 
survey by the journal Nature Biotechnol-
ogy, biotech companies reduced their 
workforce by about 38%. But throwing 
projects and employees overboard may 
not suffice, and the whole dependence 
on venture capital funding may have to 
change. “The venture capital system is 
under the most intense strain ever and 
has reduced investments in biotechnol-
ogy,” says Sharp.8, August 7, 2009 ©2009 Elsevier Inc. 413
Sharp’s colleague at MIT, Tom Knight, 
who recently founded Ginkgo Bioworks, 
a synthetic biology company in Cam-
bridge, MA, said he is not so keen to 
obtain venture capital anyway. “The ven-
ture capital community destroyed itself 
in the last five years,” says Knight. “They 
have demonstrated that they are not 
trustworthy partners in start-up com-
panies and that the only thing they care 
about is their own return, not the return 
of anyone else.” Onyvax’s Dalgleish 
agrees, “the greed of venture capital, 
who virtually expect 30% on returns, 
was extremely unrealistic.” As a result, 
“all of the smart people with really good 
ideas are avoiding venture capital like 
the plague,” emphasizes Knight. “The 
venture capital community is going to 
discover, when it wakes up next year, 
that the good deals are not available to 
them.”
But who else can finance the early 
stage funding of drug development? In 
the current void of venture capital “other 
systems that allow innovation may have 
to be created,” says Sharp. “I’m sure we 
lose innovation in the current system, 
and I’m sure we are going to lose more 
innovation within the immediate future.” 
So, continues Sharp, “perhaps it’s time 
to get government money to move inno-
vation a little closer to the marketplace.” 
But currently this seems unlikely. Indeed, 
biotech companies may not be able to 
benefit from the $10 billion in stimulus 
money allocated to the National Insti-
tutes of Health (NIH) because a clause in 
the legislation exempts the NIH from its 
usual obligation to set aside 2.8% of its 
annual budget for small businesses.
The European Model
With revenues of €11.2 billion in 2008, 
the European biotech sector is much 
smaller than its US counterpart, which 
had revenues of close to $50 billion 
in 2008; and it still lacks success sto-
ries such as Amgen or Genentech. But 
European governments have a history 
of involvement in biotech start-ups and 
so European biotech companies are less 
dependent on venture capital. Although 
about 30% of publicly traded biotech 
companies in the US have less than 6 
months of cash according to the bio-
tech merchant bank Burrill & Co., only 
one out of five European biotechs are in 414 Cell 138, August 7, 2009 ©2009 Elsevierdanger of bankruptcy by the end of 2009 
according to the trade group European 
Biopharmaceutical Enterprises. In Ger-
many, for instance, the second largest 
biotech hub in Europe after the UK, the 
biotech industry reported a 6% increase 
in sales in 2008. With a total of 400 com-
panies nationwide and sales of €1 bil-
lion per year, the German biotech sector 
cannot match the US. However, German 
biotech stocks performed about 5% bet-
ter than the average German stocks on 
the DAX index. For example, the thera-
peutic human antibody company Mor-
phosys, based near Munich, has just 
extended its collaboration with the Swiss 
pharmaceutical company Novartis until 
2017. And in the midst of the financial 
crisis, in March 2009, the Berlin-based 
company Mologen AG managed to pub-
licly raise €2.8 million to continue the 
clinical development of gene therapy to 
treat different cancers. One reason for 
this resilience is that German biotech 
companies are used to a scarcity of ven-
ture capital funding, says Burghardt Wit-
tig, who founded Mologen. Wittig sees 
a “wide and flat distribution of quality” 
in the US biotech industry from which 
“the big breakthroughs into scientifically 
and economically top levels emerge in a 
nearly stochastic but seldom rationally 
predictable way.” Thus, since the early 
days of the industry, the US has launched 
more biotech companies but also has 
lost more compared to Europe. And bio-
tech companies that would never have 
been launched in Germany or the UK 
survived in the US due to the permissive 
investment culture. Another reason for 
the resilience of German biotech com-
panies is “tremendous support from the 
government,” says Dalgleish. Germany’s 
Bioregio program and other government 
programs not only provided seed money 
of more than €600 million between 1997 
and 2005 (compared to around €500 mil-
lion in the UK) but also helped with the 
creation of a biotech landscape, inte-
grating economic, research, and com-
munity institutions together in centers 
such as Martinsried near Munich and 
Berlin-Brandenburg.
In the UK, which has the second larg-
est biotech industry after the US, more 
than 400 biotech companies generated 
about €2.5 billion in revenue in 2008. 
“The UK was fortunate in having signifi- Inc.cant capital behind several companies,” 
says Dalgleish. This got the UK biotech 
industry launched “but unfortunately due 
to the problems of a low hit rate, strict 
regulations and no government support, 
they are now much worse off than those 
in Germany and the US.” Companies 
that do not have an immediate desirable 
potential product are “likely to go to the 
wall and it is anticipated that up to 80% 
of British biotech companies needing 
funding this year could go under,” says 
Dalgleish, whose own venture Ony-
vax struggled to get a further round of 
financing to keep a clinical trial going 
and is now in administration.
In the end, biotech companies every-
where will be impacted by the current 
fiscal crisis. Although R&D spending 
by Germany’s biotech companies rose 
16% in 2007, it fell 2% to €966 million in 
2008, according to Ernst & Young. Even 
more worrying, the transfer of ideas 
from the academic sector to start-ups 
is being noticeably delayed, says Jörn 
Erselius, head of Max-Planck Innovation, 
the technology transfer company of the 
Max-Planck Society, Germany’s biggest 
non-university basic research asso-
ciation. “Definitely, the formation of new 
ventures out of Max-Planck has been 
put on ice due to the lack of financing 
opportunities.” Entrepreneurs have been 
hesitant for the last 2 or 3 years, but now 
it is even more dramatic, says Erselius.
Big Pharma to the Rescue
To maintain maneuverability, biotech 
companies are increasingly dependent 
on being bought by big pharma. The 
less capital that young biotechs have 
to finance costly phase II and III clini-
cal trials, the harder it will be for them to 
keep their independence and grow into 
new Amgens, Biogens, or Genentechs 
on their own. Big pharma also has the 
bargaining advantage now because they 
are the only ones with cash, and a recent 
wave of mergers has left fewer com-
panies interested in biotech. “Pharma 
rules now,” says Kenneth Kaitin from 
the Tufts Center for the Study of Drug 
Development in Boston, MA. Big pharma 
companies like Pfizer, Sanofi-Aventis, 
Novartis, and GlaxoSmithKline seem to 
be the only “lifeboats” available for bio-
tech companies. Last year, the Japanese 
pharma company Takeda bought Cam-
bridge-based Millennium Pharmaceuti-
cals, a vaccine developer, for $8.8 billion. 
Imclone Systems in New York, a cancer 
drug company, was acquired by Eli Lilly 
for $6.5 million, Sanofi-Aventis swal-
lowed BiPar, Novartis bought Speedel, 
and GlaxoSmithKline acquired Stiefel 
Laboratories. With $28 billion spent by 
big pharma on buying biotechs, “2008 
totted up the highest biotech M&A [merg-
ers and acquisitions] ever,” according to 
the industry bulletin FierceBiotech.
With so many biotech companies in 
tough circumstances, big pharma is 
currently in a good bargaining position, 
although they themselves need to buy 
biotech companies in order to refill their 
own dwindling drug pipelines with new 
innovative therapeutics developed by 
biotech. If there are fewer biotech ven-
tures on the market, there will be fewer 
possibilities to find the next generation 
of blockbuster drugs. “The more bio-
tech companies that fall out of their role 
as a transmitter between science and 
the big pharmaceutical companies, the 
more public money has to be provided 
to develop academic research up to 
the lead compound level, where they 
will hopefully be picked up by pharma-
ceutical companies,” says Erselius. Big 
pharma needs to engage in projects much earlier than phase I or II clinical 
trials, emphasizes Erselius. So, in the 
future, more biotech firms are likely to be 
bought by big pharma earlier in the drug 
development process. “The pipeline is 
the pipeline, whether internally or exter-
nally generated,” says Mark Fishman, 
Chief Scientific Officer of Novartis. “We 
have a good balance of short- and long-
term projects. We stick to our strategy 
over the years, driven only by scientific 
discovery. Lurching in and out of fields, 
blown by short-term financial winds, is a 
foolish strategy.” Apparently unscathed 
by the current financial crisis, “Novar-
tis continues to spend about 17% of its 
sales on R&D and to seek collaborations 
with partners in academia and biotech, 
who are innovative and who we believe 
have a technology or molecule that will 
either fill a gap or complement our inter-
nal R&D capabilities,” says Fishman.
Beyond the Horizon
The next big threat likely to buffet bio-
techs worldwide could be triggered by 
healthcare reform in the US. “What hap-
pens in the US healthcare system will 
greatly determine the effect on biotech 
and pharmaceutical companies in the 
US as well as in Europe,” says Dalgleish, 
because the US is still the biggest phar-Cell 1maceutical market with sales of about 
$315 billion in 2007. The US government’s 
Medicare program alone, which provides 
health care for people 65 years and older, 
spent $50 billion in 2008 for prescription 
drugs. The Obama administration plans 
to expand healthcare to provide cover-
age for the 47 million Americans without 
health insurance but simultaneously has 
to reduce healthcare costs, which esca-
lated in 2007 to $2.4 trillion, 17% of the 
US gross national product. Even if the 
US government does not end up regu-
lating drug prices as Europe does, the 
market forces related to a Medicare-like 
healthcare system could beat down drug 
prices, thus reducing the incentive of bio-
pharmaceutical companies to develop 
new drugs. “It’s hard to keep the bal-
ance,” says MIT’s Phillip Sharp, “to keep 
innovation in the system, control costs, 
and expand access to healthcare at the 
same time.” Overall, what shouldn’t be 
lost is the public’s need for new life-sav-
ing drugs. “Ideally the people in charge 
making these decisions understand the 
complexity of the whole process,” says 
Sharp. “What society needs to do is to 
say, I want a certain level of innovation, 
I know that there are people who are 
innovative by nature, and I will make an 
investment in these people.”
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